Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide

Cell Biol Int. 2003;27(12):953-8. doi: 10.1016/s1065-6995(03)00164-1.


Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense bcl-2 oligodeoxynucleotides enhanced the sensitivity of leukemia cells to arsenic trioxide. A combination of arsenic trioxide with antisense bcl-2 oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced bcl-2 protein expression in K562 and NB4 leukemic cells more significantly than either arsenic trioxide or the oligodeoxynucleotides on their own (P<0.01). Thus, bcl-2 antisense oligodeoxynucleotides increase the sensitivity of leukemic cells to arsenic trioxide. Combined use of the two agents could be a novel and attractive strategy in leukemia treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis
  • Arsenic Trioxide
  • Arsenicals / pharmacology*
  • Cell Division
  • Cell Line, Tumor
  • DNA / chemistry
  • Dose-Response Relationship, Drug
  • Flow Cytometry
  • Genetic Therapy / methods*
  • Humans
  • K562 Cells
  • Leukemia / drug therapy*
  • Oligonucleotides, Antisense / pharmacology*
  • Oxides / pharmacology*
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Time Factors


  • Antineoplastic Agents
  • Arsenicals
  • Oligonucleotides, Antisense
  • Oxides
  • Proto-Oncogene Proteins c-bcl-2
  • DNA
  • Arsenic Trioxide